By Monica E. Oss Navigation is all about keeping an eye on the guideposts and avoiding the obstacles ahead. This week brought more market developments that will reshape the landscape. After postponing the Trump Administration rules for expanding prescriptive ability for buprenorphine to treat opioid use disorder (OUD), the Biden Administration gave a green light to the concept. The proposed new practice guidelines are effective immediately and allow prescribers who are state licensed and registered by the Drug Enforcement Administration (DEA) to prescribe certain controlled substances with an exemption on training and certification (see HHS Releases New Buprenorphine Practice Guidelines, Expanding Access To Treatment For Opioid Use Disorder). And,…
Content Restricted

This article is reserved for members with an active membership. Please register for a Free Membership to view this resource.

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!